Search Results - "MANNS, M P"

Treating viral hepatitis C: efficacy, side effects, and complications by Manns, M P, Wedemeyer, H, Cornberg, M

“…The treatment of hepatitis C has dramatically improved over the past decade. Unlike any other chronic viral infection, a significant proportion of patients…”
Get full text

Interferon‐free therapy of chronic hepatitis C with direct‐acting antivirals does not change the short‐term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis by Mettke, F., Schlevogt, B., Deterding, K., Wranke, A., Smith, A., Port, K., Manns, M. P., Vogel, A., Cornberg, M., Wedemeyer, H.

“…Summary Background Hepatitis C virus (HCV) clearance with IFN‐based therapies reduces the incidence of hepatocellular carcinoma (HCC). There has been some…”
Get full text

Improvement of liver function parameters in advanced HCV‐associated liver cirrhosis by IFN‐free antiviral therapies by Deterding, K., Höner zu Siederdissen, C., Port, K., Solbach, P., Sollik, L., Kirschner, J., Mix, C., Cornberg, J., Worzala, D., Mix, H., Manns, M. P., Cornberg, M., Wedemeyer, H.

“…Summary Background Successful antiviral treatment of decompensated hepatitis B with HBV polymerase inhibitors is associated with improvement of liver function…”
Get full text

Senescence mirrors the extent of liver fibrosis in chronic hepatitis C virus infection by Wandrer, F., Han, B., Liebig, S., Schlue, J., Manns, M. P., Schulze‐Osthoff, K., Bantel, H.

“…Summary Background Chronic viral hepatitis is linked to fibrotic liver injury that can progress to liver cirrhosis with its associated complications. Recent…”
Get full text

Chronic Hepatitis E in Heart Transplant Recipients by Pischke, S., Stiefel, P., Franz, B., Bremer, B., Suneetha, P. V., Heim, A., Ganzenmueller, T., Schlue, J., Horn‐Wichmann, R., Raupach, R., Darnedde, M., Scheibner, Y., Taubert, R., Haverich, A., Manns, M. P., Wedemeyer, H., Bara, C. L.

“…Chronic courses of hepatitis E virus (HEV) infections have been described in immunosuppressed patients. We aimed to study the role of HEV infections in heart…”
Get full text

All‐oral direct‐acting antiviral therapy in HCV‐advanced liver disease is effective in real‐world practice: observations through HCV‐TARGET database by Reddy, K. R., Lim, J. K., Kuo, A., Di Bisceglie, A. M., Galati, J. S., Morelli, G., Everson, G. T., Kwo, P. Y., Brown, R. S., Sulkowski, M. S., Akuschevich, L., Lok, A. S., Pockros, P. J., Vainorius, M., Terrault, N. A., Nelson, D. R., Fried, M. W., Manns, M. P.

“…Summary Background Chronic hepatitis C virus therapy in patients with advanced liver disease remains a clinical challenge. HCV‐TARGET collects data in patients…”
Get full text

Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients by GRETEN, T. F, PAPENDORF, F, BLECK, J. S, KIRCHHOFF, T, WOHLBEREDT, T, KUBICKA, S, KLEMPNAUER, J, GALANSKI, M, MANNS, M. P

“…Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide. However, treatment options are limited and often inefficient. The aim of this study…”
Get full text

Molecular therapy for the treatment of hepatocellular carcinoma by Greten, T F, Korangy, F, Manns, M P, Malek, N P

“…Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide. Conventional cytotoxic chemotherapy has failed to show a substantial benefit for…”
Get full text

Detection of low HCV viraemia by repeated HCV RNA testing predicts treatment failure to triple therapy with telaprevir by Maasoumy, B., Cobb, B., Bremer, B., Luk, K., Halfon, P., Aslam, S., Manns, M. P., Cornberg, M., Wedemeyer, H.

“…Summary Background Early on‐treatment virological response is one of the most important predictors for sustained virological response (SVR) to treatment of…”
Get full text

The clinical significance of drug–drug interactions in the era of direct‐acting anti‐viral agents against chronic hepatitis C by Maasoumy, B., Port, K., Calle Serrano, B., Markova, A. A., Sollik, L., Manns, M. P., Cornberg, M., Wedemeyer, H.

“…Summary Background Drug–drug interactions (DDIs) in the treatment of chronic hepatitis C infection became a potential challenge with the introduction of…”
Get full text

Secondary sclerosing cholangitis in critically ill patients: model of end-stage liver disease score and renal function predict outcome by Voigtländer, T, Negm, A A, Schneider, A S, Strassburg, C P, Manns, M P, Wedemeyer, J, Lankisch, T O

“…Secondary sclerosing cholangitis in critically ill patients (SSC - CIP) is an underdiagnosed emerging disease. The aim of this study was to characterize…”
Get more information

Developmental aspects of human hepatic drug glucuronidation in young children and adults by Strassburg, C P, Strassburg, A, Kneip, S, Barut, A, Tukey, R H, Rodeck, B, Manns, M P

“…Background and aims: The liver represents one of the major sites of human glucuronidation. Many therapeutic drugs are substrates for…”
Get full text

Rates of sustained virological response 12 weeks after the scheduled end of direct‐acting antiviral (DAA)‐based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy? by Bischoff, J, Mauss, S, Cordes, C, Lutz, T, Scholten, S, Moll, A, Jäger, H, Cornberg, M, Manns, MP, Baumgarten, A, Rockstroh, JK

“…Objectives The European Association for the Study of the Liver (EASL) treatment recommendations for hepatitis C no longer discriminate between HIV/hepatitis C…”
Get full text

Enrichment of Regulatory T Cells in Acutely Rejected Human Liver Allografts by Taubert, R., Pischke, S., Schlue, J., Wedemeyer, H., Noyan, F., Heim, A., Lehner, F., Barg‐Hock, H., Klempnauer, J., Olek, S., Manns, M. P., Hardtke‐Wolenski, M., Jaeckel, E.

“…Acute cellular rejection (ACR) occurs frequently after liver transplantation and can usually be controlled. Triggering of allospecific immune responses and…”
Get full text

Interleukin 6 and liver regeneration by STREETZ, K L, LUEDDE, T, MANNS, M P, TRAUTWEIN, C

“…A complex of IL-6 bound to gp80 interacts on target cells with at least one gp130 molecule, thereby triggering homodimerisation of the intracellular domains of…”
Get full text

Lamivudine therapy in chronic delta hepatitis: a multicentre randomized‐controlled pilot study by NIRO, G. A., CIANCIO, A., TILLMAN, H. L., LAGGET, M., OLIVERO, A., PERRI, F., FONTANA, R., LITTLE, N., CAMPBELL, F., SMEDILE, A., MANNS, M. P., ANDRIULLI, A., RIZZETTO, M.

“…Summary Background:  Delta virus (HDV)‐related chronic hepatitis is difficult to treat. Aims:  To evaluate the efficacy of lamivudine 100 mg daily on serum…”
Get full text

Tumour necrosis factor related apoptosis inducing ligand (TRAIL) induces hepatic steatosis in viral hepatitis and after alcohol intake by Mundt, B, Wirth, T, Zender, L, Waltemathe, M, Trautwein, C, Manns, M P, Kühnel, F, Kubicka, S

“…Background and aims: Tumour necrosis factor related apoptosis inducing ligand (TRAIL) induces apoptosis in transformed cells and is considered as an agent for…”
Get full text

Basolateral ion transporters involved in colonic epithelial electrolyte absorption, anion secretion and cellular homeostasis by Bachmann, O., Juric, M., Seidler, U., Manns, M. P., Yu, H.

“…Electrolyte transporters located in the basolateral membrane of the colonic epithelium are increasingly appreciated as elaborately regulated components of…”
Get full text

Glycyrrhizin in patients who failed previous interferon alpha-based therapies: biochemical and histological effects after 52 weeks by Manns, M. P., Wedemeyer, H., Singer, A., Khomutjanskaja, N., Dienes, H. P., Roskams, T., Goldin, R., Hehnke, U., Inoue, H.

“…Chronic hepatitis C patients often fail to respond to interferon‐based therapies. This phase III study aimed at confirming the efficacy and safety of…”
Get full text

Efficacy and safety of sofosbuvir/ledipasvir for the treatment of patients with hepatitis C virus re-infection after liver transplantation by Ciesek, S., Proske, V., Otto, B., Pischke, S., Costa, R., Lüthgehetmann, M., Polywka, S., Klempnauer, J., Nashan, B., Manns, M.P., von Hahn, T., Lohse, A.W., Wedemeyer, H., Mix, H., Sterneck, M.

“…Background Hepatitis C virus (HCV) infection is associated with a particularly poor outcome after liver transplantation. In December 2014,…”
Get full text